<DOC>
	<DOCNO>NCT03037359</DOCNO>
	<brief_summary>This safety study evaluate risk low blood pressure subject Primary Immune Deficiency disorder ( PID ) treat Bivigamâ„¢ another commercial product real world condition . No study medication provide subject study . Study physician make treatment decision accord usual practice provide prescription his/her subject , appropriate . The addition collection structure documentation data generate usual practice .</brief_summary>
	<brief_title>A Study About Low Blood Pressure Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Patients PID diagnosis Current subject require treatment IGIV Patients meeting inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PID</keyword>
</DOC>